Pfizer and biontech announce positive topline results from pivotal trial of covid-19 vaccine in children 5 to 11 years

New york and mainz, germany, september 20, 2021— pfizer inc. (nyse: pfe, “pfizer”) and biontech se (nasdaq: bntx, “biontech”) today announced results from a phase 2/3 trial showing a favorable safety profile and robust neutralizing antibody responses in children 5 to 11 years of age using a two-dose regimen of 10 Μg administered 21 days apart, a smaller dose than the 30 Μg dose used for people 12 and older. the antibody responses in the participants given 10 Μg doses were comparable to those recorded in a previous pfizer-biontech study in people 16 to 25 years of age immunized with 30 Μg doses. the 10 Μg dose was carefully selected as the preferred dose for safety, tolerability and immunogenicity in children 5 to 11 years of age. these are the first results from a pivotal trial of a covid-19 vaccine in this age group.
BNTX Ratings Summary
BNTX Quant Ranking